Duopharma Biotech Sustainability Profile
Duopharma Biotech Berhad, a leading player in the pharmaceutical industry, is headquartered in Malaysia (MY) and operates extensively across Southeast Asia. Founded in 1970, the company has established itself as a key provider of generic and innovative medicines, focusing on areas such as oncology, cardiology, and anti-infectives. With a commitment to quality and affordability, Duopharma Biotech offers a diverse range of products, including prescription medications and over-the-counter solutions, distinguished by their rigorous adherence to international standards. The company has achieved significant milestones, including the introduction of Malaysia's first biosimilar product, solidifying its market position as a pioneer in biopharmaceuticals. Recognised for its contributions to healthcare, Duopharma Biotech continues to innovate, ensuring access to essential medicines while maintaining a strong commitment to sustainability and community health initiatives.
DitchCarbon Score
How does Duopharma Biotech's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Duopharma Biotech's score of 33 is higher than 54% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Duopharma Biotech's reported carbon emissions
In 2024, Duopharma Biotech reported total carbon emissions of approximately 1,839,000 kg CO2e, encompassing both Scope 1 and Scope 2 emissions. This figure remains consistent with the emissions reported for 2023, indicating a stable carbon footprint in these scopes. For the year 2022, the company disclosed a more detailed breakdown of its emissions, with Scope 1 emissions at about 1,287,990 kg CO2e, Scope 2 emissions at approximately 38,062,900 kg CO2e, and Scope 3 emissions at around 672,600 kg CO2e. This comprehensive data highlights the company's commitment to transparency in its climate impact reporting. Despite the detailed emissions data for 2022, Duopharma Biotech has not set specific reduction targets or initiatives, as indicated by the absence of documented reduction targets or commitments to frameworks such as the Science Based Targets initiative (SBTi). The company has not cascaded any emissions data from a parent organization, maintaining its own reporting standards. Overall, while Duopharma Biotech has demonstrated a commitment to reporting its emissions, the lack of defined reduction strategies suggests an opportunity for the company to enhance its climate commitments in the future.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Scope 1 | 1,115,210 | 0,000,000 | 0,000,000 | 0,000,000 | - | - |
| Scope 2 | 23,063,600 | 00,000,000 | 00,000,000 | 00,000,000 | - | - |
| Scope 3 | - | - | 0,000,000 | 000,000 | - | - |
How Carbon Intensive is Duopharma Biotech's Industry?
How Carbon Intensive is Duopharma Biotech's Location?
Duopharma Biotech's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Duopharma Biotech has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
